| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0959-8049(00)00078-2 |
| P698 | PubMed publication ID | 10908846 |
| P2093 | author name string | F A Greco | |
| J D Hainsworth | |||
| A A Meluch | |||
| H S Burris | |||
| P2860 | cites work | M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience | Q33376563 |
| Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 | ||
| Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 | ||
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 | ||
| Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 | ||
| Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter | Q36116031 | ||
| The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). | Q40713819 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel | Q57905110 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer | Q68891233 | ||
| Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience | Q69654530 | ||
| Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy | Q71667709 | ||
| Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma | Q73181726 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| P921 | main subject | paclitaxel | Q423762 |
| transitional cell carcinoma | Q2501186 | ||
| P304 | page(s) | 30-33 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium | |
| P478 | volume | 36 Suppl 2 |
| Q45114047 | A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer |
| Q44635857 | A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma |
| Q40708483 | Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer |
| Q34438928 | Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. |
Search more.